Clinical trials: Depression Symptom
Panic Disorder, Depression
Drug Use Investigation of Jzoloft.
The objective of this surveillance is to collect information about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00605865
- Testing
- Sertraline hydrochloride
- Volunteers
- 2,272 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depression
Neural Mechanisms With CES in Depression
This study will examine the effect of cranial electrotherapy stimulation (CES) treatment on adults with depression. Scalp based electroencephalogram (EEG) will be utilized to record the brain activity of participants whilst they…
- Trial name
- NCT04587531
- Testing
- Cranial Electrotherapy Stimulation
- Where
- United Kingdom
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Electromedical Products International, Inc.
Respiratory Depression
Long-term Extension Study of BEMA™ Fentanyl
This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.
- Trial name
- NCT00696137
- Testing
- BEMA Fentanyl
- Volunteers
- 5 people
- Sponsor
- BioDelivery Sciences International
Hypogonadism, Late Onset Hypogonadism
Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80
The purpose of this study is to evaluate whether DHT-Gel, when applied daily to the skin, can relieve the symptoms of low testosterone in men aged 55-80.
- Conditions
- Hypogonadism, Late Onset Hypogonadism, Low Testosterone
- Trial name
- NCT00163566
- Testing
- Dihydrotestosterone (0.7%) in hydroalcoholic gel
- Where
- 16 sites in United States
- Volunteers
- 128 people
- Sponsor
- ASCEND Therapeutics
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression
Bioequivalency Study of Sertraline Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00602849
- Testing
- Sertraline
- Where
- Canada
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868699
- Testing
- lurasidone
- Where
- 55 sites in United States, Czechia and 6 more
- Volunteers
- 505 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depression
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.
- Trial name
- NCT00864981
- Testing
- Bupropion HCI ER Tablets, 150 mg; EON Labs Inc., WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control.
- Trial name
- NCT00385307
- Testing
- amibegron (SR58611A)
- Where
- United States
- Volunteers
- 680 people
- Sponsor
- Sanofi
Major Depressive Disorder
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.
- Trial name
- NCT00109044
- Testing
- Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 540 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Major Depressive Disorder
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06963021
- Testing
- NBI-1065845
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Depressive Disorder and Anxiety Disorders
A First Time in Human Study of GSK586529 in Healthy Volunteers
A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male subjects. Subjects will be divided into two cohorts with alternate panel design.
- Trial name
- NCT00703547
- Testing
- GSK586529 capsules, GSK586529 tablets
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anxiety, Depression
NeuroGlove Anxiety and Depression Study
This is a prospective, homebased, interventional clinical study containing 10 subjects who will be enrolled. Approximately 10 (10) subjects with active anxiety and depression symptoms will receive treatment using the NeuroGlove.
- Conditions
- Anxiety, Depression, Anxiety Depression, Depression, Anxiety
- Trial name
- NCT06065787
- Testing
- NeuroGlove
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NeuroGlove LLC
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04533529
- Testing
- Seltorexant
- Where
- 122 sites in United States, Brazil and 9 more
- Volunteers
- 588 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Major Depressive Disorder
Effect of SSRIs on Response to Psilocybin Therapy
This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting.
- Conditions
- Depression, Major Depressive Disorder, Mild Depression, Moderate Depression
- Trial name
- NCT05594667
- Testing
- Psilocybin
- Where
- Canada
- Sponsor
- Cybin Therapeutics Inc.